Eli Lilly And Company (LLY): Today's Featured Health Care Laggard
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
Eli Lilly and Company ( LLY) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole was unchanged today. By the end of trading, Eli Lilly and Company fell $0.63 (-1.1%) to $55.38 on average volume. Throughout the day, 4,533,952 shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 5,414,800 shares. The stock ranged in price between $55.16-$55.90 after having opened the day at $55.90 as compared to the previous trading day's close of $56.01. Other companies within the Health Care sector that declined today were: Delcath Systems ( DCTH), down 40.1%, AVEO Pharmaceuticals ( AVEO), down 31.3%, Neostem ( NBS), down 20.6% and Cormedix ( CRMD), down 16.8%.
- EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $63.7 billion and is part of the drugs industry. The company has a P/E ratio of 14.5, below the S&P 500 P/E ratio of 17.7. Shares are up 14.5% year to date as of the close of trading on Monday.
TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, growth in earnings per share and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.
- You can view the full Eli Lilly and Company Ratings Report .
On the positive front, Transition Therapeutics ( TTHI), down 37.8%, Pain Therapeutics ( PTIE), down 26.0%, Durect Corporation ( DRRX), down 25.6% and Bacterin International Holdings ( BONE), down 18.1% , were all gainers within the health care sector with Tenet Healthcare ( THC) being today's featured health care sector leader.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists .
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).